JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2008, 57(4):181-186

Monitoring of pharmacotherapy in seniors of rest homes in Brno region

L. Bartošíková1,*, J. Nečas1, T. Bartošík2, J. Fráňová3
1 Univerzita Palackého v Olomouci, Lékařská fakulta, Ústav fyziologie
2 Fakultní nemocnice U sv. Anny v Brně, Anesteziologicko-resuscitační klinika
3 Fakultní nemocnice Brno, Dětská nemocnice, II. dětská klinika

Polypharmacy is a problem of growing importance in today's medicine. It has many negative impacts on the patient and healthcare system alike. Seniors with multiple co-morbidities are more likely to be on multiple medications, and therefore they are at higher risk of developing serious side effects or interactions. The aim of the study was to monitor pharmacotherapy of seniors in the rest homes in the Brno region. The study included 72 patients, 26 men and 46 women, of the average age of 84.9 years. Polypharmacy was detected in 92% cases. The number of the most widely prescribed drugs which were medicated in 10 or more patients is 13. Drug interactions are risk of pharmacotherapy but it is possible to avoid them by reduction of polypharmacy.

Keywords: polypharmacy; seniors; drug interactions

Received: May 12, 2008; Accepted: June 15, 2008; Published: April 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bartošíková L, Nečas J, Bartošík T, Fráňová J. Monitoring of pharmacotherapy in seniors of rest homes in Brno region. Čes. slov. farm. 2008;57(4):181-186.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Endoh, M.: Cardiovasc. Drug. Ther., 2001; 15, 379-403. Go to original source...
    2. Flesch, M., Erdmann, E.: Cardiovasc. Drug. Rev., 2001; 15, 379-386. Go to original source... Go to PubMed...
    3. Cheb, P. D., Bhatt, D. I., Topol, E. J., Oral, G. P.: Cardiovasc. Drug., 2001; 6, 421-428. Go to original source... Go to PubMed...
    4. Plevová, J., Boleloucký, Z.: Psychofarmakoterapie vyššího věku, 2. vyd. Praha, Grada Publishing, 2000, s. 164.
    5. Topinková, E.: Geriatrie pro praxi, 1. vyd. Praha, Galén, 2005, s. 270.
    6. Motlová, L., Holub, D.: Remedia, 2005; 6, 514-516. Go to original source...
    7. Záboj, Z.: Prakt. Lék., 2000; 2, 99-101.
    8. Novotný, T.: Medical Tribune, 2005; 16, 9.
    9. Strojil, J., Horák, F., Arge, J.: Klin. Farmakol. farm., 2007; 1, 43-45.
    10. Alušík, Š.: Vnitř. Lék., 1999; 5, 315-318.
    11. Gruberová, B.: Gerontologie, 1. vyd. České Budějovice, Jihočeská univerzita, Zdravotně sociální fakulta, 1998, s. 86.
    12. Kriška, M. et al.: Memorix klinickej farmakologie, 1. vyd. Bratislava, Slovac Academic Press, 2002, s. 897.
    13. Kriška, M. et al.: Riziko liekov v medicínskéj praxi. 1. vyd. Bratislava, Slovak Academic Press, 2000, s. 474.
    14. Hegyi, L.: Geriatria, 2005; 2, 78-82. Go to original source...
    15. Křivohlavý, J.: Prakt. Lék., 2000; 5, 272-275. Go to original source...
    16. Katzung. B. G.: Základní a klinická farmakologie, 2. vyd. Praha, Nakladatelství a vydavatelství H & H, 1995, s. 1072.
    17. Bertilsson, L., Dahl, M. L., Dalen, P., Al-Shurbaji, A.: Brit. J. Clin. Pharmacol., 2002; 53, 111-122. Go to original source... Go to PubMed...
    18. Bultas, J., Doležal, T.: Remedia, 2001; 2, 157-161.
    19. Michalets, E. I.: Pharmacotherapy, 1998; 1, 84-112. Go to original source...
    20. Fialová, D., Topinková, E.: Remedia, 2005; 4-5, 410-417.
    21. Topinková, E., Fialová, D.: Postgrad. Med., 2002; 4, 477-482.
    22. Baštecký, J. et al.: Gerontopsychiatrie, 1. vyd. Praha, Grada Avicenum, 1994, s. 320.
    23. Gates, J. D.: Long term network: EDA 313-0198, 2000.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.